SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility amid allegations of a pump-and-dump scheme, sparking intense debate between traders labeling it a fraudulent manipulation and those betting on its potential through upcoming event-driven catalysts. While proponents point to real-world integration and event partnerships as drivers for growth, the community remains deeply polarized over concerns regarding highly concentrated supply ownership and the potential for a sudden, sharp decline.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a historical artifact of crypto culture, with investors highlighting its 2011 origin and recent tokenization as evidence of its enduring relevance. The community is actively debating its potential to reach billion-dollar market status, citing accumulation by high-net-worth wallets and the narrative strength of being the original parody of Bitcoin.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors digest a series of positive regulatory and clinical updates, including a significant executive order from the Trump administration aimed at accelerating FDA review processes for psychedelic-assisted therapies. Community sentiment is largely focused on the potential for reduced clinical timelines and the impact of upcoming late-stage trial readouts, fueling speculative volume and institutional interest in the broader psychedelic biotech sector.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

The community is actively monitoring the Roundhill Ether Covered Call Strategy ETF for its consistent weekly dividend distributions, despite varied sentiment regarding the fund's net asset value performance. Investors are balancing the appeal of high-yield income strategies against the inherent volatility of the underlying Ethereum market as they track upcoming distribution announcements.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors debate the impact of ongoing token dilution against potential catalysts like a pending Cronos ETF and broader ecosystem expansion. While some users express frustration over the asset's price stagnation relative to Bitcoin, others are actively accumulating the coin, viewing the current range as a strategic entry point for long-term growth.

Daddy Darth Vader

The community is actively engaged in a rivalry known as the 'Daddy Wars' between $DARTH, $SIDIOUS, and $MAULCOIN, with discussions dominated by debates over developer transparency, liquidity strategies, and community-driven token giveaways. Participants are speculating on the next parabolic breakout while trading insults and tips regarding entry points in these highly volatile nano-cap assets.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining traction as a high-risk, micro-cap AI narrative play, with investors highlighting its potential for Anthropic pre-IPO exposure and comparing its long-term growth prospects to established projects like Render.

Procure ETF Trust II - Procure Space ETF

Procure Space ETF is currently a focal point for investors as the broader space industry anticipates the upcoming SpaceX IPO, generating significant discussion about how to best gain exposure to the sector. Community sentiment remains mixed, with some actively debating the fund's holdings, specifically questioning whether it serves as a pure-play investment or if its inclusion of defense and communications companies dilutes the focus on pure aerospace innovation.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is currently in the spotlight following the announcement of positive Phase 2 signal detection study results for its HLP004 anxiety therapeutic, even as investors grapple with significant volatility and the company's recent rebranding to the "HELP" ticker. Community discourse is sharply divided between long-term holders encouraged by institutional backing and a robust patent portfolio, and skeptical participants highlighting historical dilution concerns and the risks inherent in a clinical-stage biotech navigating a complex regulatory environment.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing a significant surge in momentum as the psychedelic biotech sector reacts to a new executive order that fast-tracks regulatory pathways for psychedelic-assisted therapies. Investors are actively debating the company's valuation, phase 3 clinical trial prospects, and its potential to be a high-premium buyout candidate, though sentiment remains divided between those betting on policy-driven breakthroughs and skeptics focused on historical volatility and cash burn concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
